Fig. 1
From: Predicting potential adverse events using safety data from marketed drugs
Characteristics of test drugs, comparator drugs and test-comparator drug combinations. a) Distribution of number of comparator drugs for test drug. b) Distribution of time on market for test drugs. c) Tanimoto score distribution for test-comparator drug combinations. d) Target similarity score distribution for test-comparator drug combinations. e) Distribution of time on market for comparator drugs